230 related articles for article (PubMed ID: 28017788)
1. Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non-Small Cell Lung Cancer.
Usui Y; Udagawa H; Matsumoto S; Imai K; Ohashi K; Ishibashi M; Kirita K; Umemura S; Yoh K; Niho S; Osame K; Goto K
J Thorac Oncol; 2017 May; 12(5):e41-e43. PubMed ID: 28017788
[No Abstract] [Full Text] [Related]
2. Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.
Pellegrino B; Musolino A; Tiseo M
Ann Oncol; 2017 Jun; 28(6):1405-1406. PubMed ID: 28383638
[No Abstract] [Full Text] [Related]
3. Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient.
Ricciuti B; Metro G; Baglivo S; Colabrese D; Chiari R; Bennati C; Paglialunga L
J Thorac Oncol; 2017 May; 12(5):e51-e55. PubMed ID: 28434516
[No Abstract] [Full Text] [Related]
4. Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab.
Matsumura K; Nagasawa K; Oshima Y; Kikuno S; Hayashi K; Nishimura A; Okubo M; Uruga H; Kishi K; Kobayashi T; Mori Y
J Diabetes Investig; 2018 Mar; 9(2):438-441. PubMed ID: 28418115
[TBL] [Abstract][Full Text] [Related]
5. A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms.
Ishikawa K; Shono-Saito T; Yamate T; Kai Y; Sakai T; Shimizu F; Yamada Y; Mori H; Noso S; Ikegami H; Kojima H; Tanaka H; Fujiwara S; Hatano Y
Eur J Dermatol; 2017 Apr; 27(2):184-185. PubMed ID: 27934619
[No Abstract] [Full Text] [Related]
6. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.
Matsuura N; Koh G; Konishi C; Minamino S; Takahara Y; Harada H; Kodama K; Emoto M
Cancer Immunol Immunother; 2018 Sep; 67(9):1417-1424. PubMed ID: 29995236
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
8. Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
Caponnetto S; Iannantuono GM; Barchiesi G; Magri V; Gelibter A; Cortesi E
Oncology; 2017; 93(1):62-66. PubMed ID: 28407622
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients.
Puszkiel A; Noé G; Boudou-Rouquette P; Cossec CL; Arrondeau J; Giraud JS; Thomas-Schoemann A; Alexandre J; Vidal M; Goldwasser F; Blanchet B
J Pharm Biomed Anal; 2017 May; 139():30-36. PubMed ID: 28260630
[TBL] [Abstract][Full Text] [Related]
10. Acute-onset type 1 diabetes mellitus caused by nivolumab in a patient with advanced pulmonary adenocarcinoma.
Kumagai R; Muramatsu A; Nakajima R; Fujii M; Kaino K; Katakura Y; Okumura N; Ohara G; Kagohashi K; Satoh H; Yagyu H
J Diabetes Investig; 2017 Nov; 8(6):798-799. PubMed ID: 29098805
[TBL] [Abstract][Full Text] [Related]
11. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
[TBL] [Abstract][Full Text] [Related]
12. Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab.
Taniguchi Y; Tamiya A; Isa SI; Nakahama K; Okishio K; Shiroyama T; Suzuki H; Inoue T; Tamiya M; Hirashima T; Imamura F; Atagi S
Anticancer Res; 2017 Oct; 37(10):5857-5862. PubMed ID: 28982912
[TBL] [Abstract][Full Text] [Related]
13. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.
Kawakami H; Tanizaki J; Tanaka K; Haratani K; Hayashi H; Takeda M; Kamata K; Takenaka M; Kimura M; Chikugo T; Sato T; Kudo M; Ito A; Nakagawa K
Invest New Drugs; 2017 Aug; 35(4):529-536. PubMed ID: 28317087
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
Feng Y; Wang X; Bajaj G; Agrawal S; Bello A; Lestini B; Finckenstein FG; Park JS; Roy A
Clin Cancer Res; 2017 Sep; 23(18):5394-5405. PubMed ID: 28916617
[No Abstract] [Full Text] [Related]
15. Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.
Mahjoubi L; Gazzah A; Marabelle A; Le Roy Ladurie F; Lambotte O; Caramella C; Adam J; Besse B; Soria JC
Eur J Cancer; 2017 Nov; 85():155-157. PubMed ID: 28917814
[No Abstract] [Full Text] [Related]
16. Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab.
Turgeman I; Wollner M; Hassoun G; Bonstein L; Bar-Sela G
Anticancer Drugs; 2017 Aug; 28(7):811-814. PubMed ID: 28574922
[TBL] [Abstract][Full Text] [Related]
17. Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer.
Rampinelli C; Spitaleri G; Passaro A; Pochesci A; Ancona E; De Marinis F
Am J Respir Crit Care Med; 2017 Nov; 196(10):1349-1350. PubMed ID: 28910131
[No Abstract] [Full Text] [Related]
18. Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence.
Yoshida T; Furuta H; Hida T
Med Oncol; 2017 Mar; 34(3):34. PubMed ID: 28138869
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study.
Ulmeanu R; Antohe I; Anisie E; Antoniu S
Expert Rev Anticancer Ther; 2016; 16(2):165-7. PubMed ID: 26634873
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy.
Bebb G; Smith C; Rorke S; Boland W; Nicacio L; Sukhoo R; Brade A
Cancer Chemother Pharmacol; 2011 Apr; 67(4):837-45. PubMed ID: 20563810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
